Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

BACKGROUND: Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. METHODS: Open-label, nonrandomized, multicenter, phase 3 study to validate the (18)F-labeled β-amyloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology. RESULTS: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty-six of 47 neuritic β-amyloid-positive cases were read as PET positive, and 24 of 27 neuritic β-amyloid plaque-negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8-100%], specificity 88.9% [95% CI 77.0-100%]). In a subgroup, a regional tissue-scan matched analysis was performed. In areas known to strongly accumulate β-amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. CONCLUSIONS: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology-confirmed neuritic β-amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. TRIAL REGISTRATION: ClinicalTrials.govNCT01020838.

What this study adds

Evidence grade: Not rated

A phase 3 study compared florbetaben PET scans with brain tissue examined after death in 74 people. Scans were read as positive in 46 of 47 cases with amyloid plaques and negative in 24 of 27 cases without, and the authors say the scan may be a valuable adjunct to clinical diagnosis, particularly for ruling out Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sabri, O., Sabbagh, M. N., Seibyl, J. P., Barthel, H., Akatsu, H., Ouchi, Y., et al. (2015). Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2015.02.004

Vancouver

Sabri O, Sabbagh MN, Seibyl JP, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimer s & Dementia. 2015. doi:10.1016/j.jalz.2015.02.004. PMID: 25824567.

BibTeX

@article{sabri2015-25824567,
  author  = {Sabri, Osama and Sabbagh, Marwan Noel and Seibyl, John Peter and Barthel, Henryk and Akatsu, Hiroyasu and Ouchi, Yasuomi and 仙田, 宏平 and Murayama, Shigeo and Ishii, Kenji and Takao, Masaki and Beach, Thomas G. and Rowe, Christopher Cleon and Leverenz, James B. and Ghetti, Bernardino Francesco and Ironside, James W. and Catafau, Ana María and Stephens, Andrew Wills and Mueller, André and Koglin, Norman and Hoffmann, Anja and Roth, Katrin Sabine and Reininger, Cornelia B and Schulz‐Schaeffer, Walter and {Florbetaben Phase 3 Study Group}},
  title   = {{Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study}},
  journal = {Alzheimer s \& Dementia},
  year    = {2015},
  doi     = {10.1016/j.jalz.2015.02.004},
  pmid    = {25824567},
  url     = {https://doi.org/10.1016/j.jalz.2015.02.004}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 24 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Why it matters

A phase 3 study compared florbetaben PET scans with brain tissue examined after death in 74 people. Scans were read as positive in 46 of 47 cases with amyloid plaques and negative in 24 of 27 cases without, and the authors say the scan may be a valuable adjunct to clinical diagnosis, particularly for ruling out Alzheimer's disease.

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 0 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 48 of the 91 points it could be judged on, which is 53 of 100. Total 53 of 100.48 of the 91 points we could judge = 53 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence and senior author's track record, so those were left out: it earned 48 of the 91 points we could judge it on, which is 53 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 604 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 46.5 citations a year over 13 year(s) since 2015
Impact for its field and year 5 / 6 Cited 35.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 3 / 4 Cited 177 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 21 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25824567)
Free to read 2 / 2 Free to read
Points 48 / 91 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 48 of the 91 points we could judge it on is 53 out of 100.
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain scans and imaging from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →